Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E9AF
|
|||
| Former ID |
DIB007613
|
|||
| Drug Name |
ALN-TTRsc
|
|||
| Synonyms |
SAR438714
Click to Show/Hide
|
|||
| Indication | Cardiomyopathy [ICD-11: BC43] | Phase 3 | [1] | |
| Company |
Alnylam pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transthyretin (TTR) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | Retinoid cycle disease events | |||
| The canonical retinoid cycle in rods (twilight vision) | ||||
| Non-integrin membrane-ECM interactions | ||||
| Retinoid metabolism and transport | ||||
| Amyloid formation | ||||
| WikiPathways | Visual phototransduction | |||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02319005) ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.